



**Cancer Control Program
Symptom Intervention Committee**

200 First Street, SW
Rochester, MN 55905
P: 507-266-9202
F: 507-284-1803

www.allianceforclinicaltrialsinoncology.org

Charles L. Loprinzi, M.D.
Chair

**Agenda
Symptom Intervention Committee Meeting
Friday November 6, 2015
8:00 – 10:00 AM CT
Room: Guggenheim 1**

Meeting available by teleconference: Dial 800-501-8979 Access Code: 7181781

Symptom Intervention Committee Leadership:		
Charles L. Loprinzi, MD	Chair	clopinzi@mayo.edu
Andrew L. Himmelstein, MD	Co-vice Chair	ahimmelstein@cbg.org
Kathryn J. Ruddy, MD	Co-vice Chair	Ruddy.Kathryn@mayo.edu
Ellen L. Smith, PhD	Co-vice Chair	ellenls@med.umich.edu
Jan C. Buckner, MD	CCP Program Director	buckner.jan@mayo.edu
Jacqueline M. Lafky, MS	CCP Program Manager	lafky.jacqueline@mayo.edu
Deborah Dickman	CCP Administrative Assistant	dickman.deborah@mayo.edu

- I. **New Concepts**
- II. **Status of Concepts**
- III. **Recently Opened Protocols**
- IV. **Other Open Studies**
- V. **Associated Pilot Trials**
- VI. **Studies Recently Closed, Being Analyzed**
- VII. **Abstracts Since May 2015**
- VIII. **Publications Since May 2015**
- IX. **Other Business**

Publications Since May 2015

Symptom Intervention – Primary Committee Manuscripts

- Boora, GK, Kulkarni, AA, Kanwar, R, Beyerlein, P, Qin, R, Banck, MS, Ruddy, KJ, Pleticha, J, Lynch, CA, Behrens, RJ, Zuchner, S, Loprinzi, CL and Beutler, AS. "Association of the Charcot-Marie-Tooth Disease Gene ARHGEF10 with Paclitaxel Induced Peripheral Neuropathy in NCCTG N08CA (Alliance)." *J Neurol Sci*. 2015 Oct 15; 357(1-2): 35-40. PMID: 26143528. PMCID: PMC4575633. (Study ID: N08CA)
- Kulkarni, AA, Boora, G, Kanwar, R, Ruddy, KJ, Banck, MS, Le-Lindqwister, N, Therneau, TM, Loprinzi, CL and Beutler, AS. "RWDD3 and TECTA Variants Not Linked to Paclitaxel Induced Peripheral Neuropathy in North American Trial Alliance N08C1." *Acta Oncol*. 2015 Sep; 54(8): 1227-1229. PMID: 25549536. PMCID: PMC4490132. (Study ID: N08C1)
- Pachman, DR, Qin, R, Seisler, D, Smith, EM, Beutler, AS, Ta, LE, Lafky, JM, Wagner Johnston, ND, Ruddy, KJ, Dakhil, S, Staff, NP, Grothey, A and Loprinzi, CL. "Clinical Course of Oxaliplatin-Induced Neuropathy: Results from the Randomized Phase III Trial N08CB (Alliance)." *J Clin Oncol*. 2015 Oct 20; 33(30): 3416-3422. PMID: 26282635. PMCID: PMC4606060. (Study ID: N08CB)
- Park, H, Qin, R, Smith, TJ, Atherton, PJ, Barton, DL, Sturtz, K, Dakhil, SR, Anderson, DM, Flynn, K, Puttabasavaiah, S, Le-Lindqwister, NA, Padula, GD and Loprinzi, CL. "North Central Cancer Treatment Group N10C2 (Alliance): A Double-blind Placebo-controlled Study of Magnesium Supplements to Reduce Menopausal Hot Flashes." *Menopause*. 2015 Jun; 22(6): 627-632. PMID: 25423327. PMCID: PMC4442087. (Study ID: N10C2)
- Wagner-Johnston, ND, Sloan, JA, Liu, H, Kearns, AE, Hines, SL, Puttabasavaiah, S, Dakhil, SR, Lafky, JM, Perez, EA and Loprinzi, CL. "5 year Follow-up of a Randomized Controlled Trial of Immediate versus Delayed Zoledronic Acid for Prevention of Bone Loss in Postmenopausal Women with Breast Cancer Starting Letrozole after Tamoxifen- N03CC." *Cancer*. 2015 Aug 1; 121(15): 2537-2543. PMID: 25930719. PMCID: PMC4512885. (Study ID: N03CC)
- Zimmerman, C, Atherton, PJ, Pachman, D, Seisler, D, Wagner-Johnston, N, Dakhil, S, Lafky, JM, Qin, R, Grothey, A and Loprinzi, CL. "MC11C4: A Pilot Randomized, Placebo-controlled, Double-blind Study of Venlafaxine to Prevent Oxaliplatin-induced Neuropathy." *Support Care Cancer*. 2015 Aug 8. PMID: 26248652. [Epub ahead of print] (Study ID: MC11C4, CALGB CCOP-funded pilot)

Symptom Intervention – Primary Committee Abstracts

- Himelstein, AL, Qin, R, Novotny, PJ, Seisler, DK, Khatcheressian, JL, Roberts, JD, Grubbs, SS, O'Connor, T, Weckstein, D, Loprinzi, CL and Shapiro, CL. "CALGB 70604 (Alliance): A Randomized Phase III Study of Standard Dosing vs. Longer Interval Dosing of Zoledronic Acid in Metastatic Cancer." *ASCO Meeting Abstracts*. 2015 May 18, 2015; 33(15_suppl): 9501. Oral Presentation. http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/9501. (Study ID: 70604)
- Navari, RM, Qin, R, Ruddy, KJ, Liu, H, Powell, SF, Bajaj, M, Dietrich, LL, Lafky, JM and Loprinzi, CL. "Olanzapine for the Prevention of Chemotherapy-induced Nausea and Vomiting (CINV) in Patients Receiving Highly Emetogenic Chemotherapy (HEC): Alliance A221301, A Randomized, Double-blind, Placebo-controlled Trial." *J Clin Oncol*. 2015 Oct; 33(suppl 29S): abstr 176. Oral and Poster Presentation. <http://meetinglibrary.asco.org/content/155048-165>. (Study ID: A221301)
- Ruddy, KJ, Pachman, D, Qin, R, Seisler, DK, Smith, EML, Puttabasavaiah, S, Novotny, PJ, Ta, LE, Beutler, AS, Wagner-Johnston, ND, Staff, N, Grothey, A, Dakhil, SR and Loprinzi, CL. "A Comparison of the Natural History of Oxaliplatin- and Paclitaxel-induced Neuropathy (NCCTG N08C1, N08CB/Alliance)." *ASCO Meeting Abstracts*. 2015 May 18, 2015; 33(15_suppl): 9564. Poster Presentation. http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/9564. (Study ID: A151505, N08C1, N08CB)
- Smith, EML, Yang, J, Banerjee, T, Loprinzi, C, Cavaletti, G, Bridges, C, Haupt, R, Kanzawa, G, Knoerl, R, Lee-Ekblad, D and Prasertsri, N. "The Reliability, Validity, and Sensitivity of the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Chemotherapy-induced Peripheral Neuropathy (QLQ-CIPN-20)." Accepted Abstract. 2016 Midwest Nursing Research Society. (Study IDs: N06CA, N08C1, N08CA, N08CB)
- Zimmerman, C, Atherton, P, Pachman, D, Seisler, D, Wagner-Johnston, N, Dakhil, S, Lafky, J, Qin, R, Grothey, A and Loprinzi, C. "Venlafaxine to Prevent Oxaliplatin-Induced Neuropathy? A Pilot Randomized Placebo Controlled Trial." *Support Care Cancer*. 2015 June; 23(Suppl 1): S152 (abstract 112-106-P). Poster Presentation. http://mascc2015.kenes.com/Documents/10.1007_s00520-015-2712-y.pdf. (Study ID: MC11C4, CALGB CCOP-funded pilot)
- Zimmerman, CT, Atherton, PJ, Pachman, DR, Seisler, DK, Wagner-Johnston, ND, Dakhil, SR, Lafky, JM, Qin, R, Grothey, A and Loprinzi, CL. "Venlafaxine to Prevent Oxaliplatin-induced Neuropathy?: A Pilot Randomized Placebo-controlled Trial." *ASCO Meeting Abstracts*. 2015 May 18, 2015; 33(15_suppl): e20734. http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/e20734. Publication Only. (Study ID: MC11C4, CALGB CCOP-funded pilot)

Symptom Intervention – Secondary Committee Manuscripts

- Dueck, AC, Singh, J, Atherton, P, Liu, H, Hines, S, Loprinzi, CL, Perez, EA, Mincey, BA, Tan, A, Burger, K, Zhao, C, Diekmann, B and Sloan, JA. "Endpoint Comparison for Bone Mineral Density Measurements in North Central Cancer Treatment Group Cancer Clinical Trials N02C1 and N03CC (Alliance)." *Osteoporosis International*. 2015 Jul; 26(7): 1971-1977. PMID: 25749740. PMCID: PMC4484303. (Study ID: N02C1 and N03CC)